Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| growth hormone derivatives | 5413 | 1338578-34-9 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Somapacitan-beco is a human growth hormone (hGH) analog. It binds to a dimeric GH receptor in the cell membrane of target cells resulting in intracellular signal transduction and a host of pharmacodynamic effects. Some of these pharmacodynamic effects are primarily mediated by insulin-like growth factor I (IGF-I) produced in the liver, while others are primarily a consequence of the direct effects of somapacitan-beco.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 28, 2020 | FDA | NOVO NORDISK INC | |
| March 31, 2021 | EMA | Novo Nordisk A/S | |
| June 26, 2023 | PMDA | Novo Nordisk Pharma Ltd. |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | H01AC07 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES Somatropin and somatropin agonists |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Adult growth hormone deficiency | indication | 421684006 | |
| Diabetic retinopathy | contraindication | 4855003 | DOID:8947 |
| Malignant neoplastic disease | contraindication | 363346000 | DOID:162 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Growth hormone receptor | Membrane receptor | Kd | 8.04 | SCIENTIFIC LITERATURE | DRUG LABEL |
| ID | Source |
|---|---|
| D11194 | KEGG_DRUG |
| 8FOJ430U94 | UNII |
| C4726770 | UMLSCUI |
| CHEBI:755778 | CHEBI |
| JG5 | PDB_CHEM_ID |
| CHEMBL3707290 | ChEMBL_ID |
| 129894493 | PUBCHEM_CID |
| DB15093 | DRUGBANK_ID |
| 10019 | INN_ID |
| C000718308 | MESH_SUPPLEMENTAL_RECORD_UI |
| C000594654 | MESH_SUPPLEMENTAL_RECORD_UI |
| 898157004 | SNOMEDCT_US |
| 4042238 | VANDF |
| 4042239 | VANDF |
| 338169 | MMSL |
| 38779 | MMSL |
| d09620 | MMSL |
| 018501 | NDDF |
| 2557373 | RXNORM |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| SOGROYA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0169-2030 | INJECTION, SOLUTION | 6.70 mg | SUBCUTANEOUS | BLA | 32 sections |
| SOGROYA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0169-2035 | INJECTION, SOLUTION | 3.30 mg | SUBCUTANEOUS | BLA | 32 sections |
| SOGROYA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0169-2037 | INJECTION, SOLUTION | 10 mg | SUBCUTANEOUS | BLA | 32 sections |